De Caterina, R., Agewall, S., Andreotti, F., Angiolillo, D. J., Bhatt, D. L., Byrne, R. A., … Galli, M. (2022). Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. Eur Heart J, 43(37), 3512–3527. https://doi.org/10.1093/eurheartj/ehac294

De Caterina, Raffaele, Stefan Agewall, Felicita Andreotti, Dominick J. Angiolillo, Deepak L. Bhatt, Robert A. Byrne, Jean-Philippe Collet, et al. “Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.” Eur Heart J 43, no. 37 (October 7, 2022): 3512–27. https://doi.org/10.1093/eurheartj/ehac294.

De Caterina R, Agewall S, Andreotti F, Angiolillo DJ, Bhatt DL, Byrne RA, et al. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. Eur Heart J. 2022 Oct 7;43(37):3512–27.

De Caterina, Raffaele, et al. “Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.” Eur Heart J, vol. 43, no. 37, Oct. 2022, pp. 3512–27. Pubmed, doi:10.1093/eurheartj/ehac294.

De Caterina R, Agewall S, Andreotti F, Angiolillo DJ, Bhatt DL, Byrne RA, Collet J-P, Eikelboom J, Fanaroff AC, Gibson CM, Goette A, Hindricks G, Lip GYH, Potpara T, Thiele H, Lopes RD, Galli M. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. Eur Heart J. 2022 Oct 7;43(37):3512–3527.